To overcome this concern, the expression levels or responses of the six markers could be incorporated into a composite ‘NRF2 activity score’, in a similar manner to a number of recent studies that have used this type of bioinformatic approach to categorise tumours exhibiting high or low NRF2 activity and link this measure to patient outcomes [[44], [45], [46]]. This evidence concerns the gene NFE2L2 and neoplasm.